{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T10:41:46Z","timestamp":1788172906004,"version":"build-2803163510"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015511","name":"Wockhardt Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015511","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014825","name":"Biotechnology Industry Research Assistance Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014825","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Southeast Asia"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.lansea.2025.100666","type":"journal-article","created":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T10:48:15Z","timestamp":1758710895000},"page":"100666","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Efficacy and safety of a 3-day once-daily regimen of oral nafithromycin in comparison to oral moxifloxacin for the treatment of community-acquired bacterial pneumonia in adults: a phase III, randomized, double-blind controlled trial"],"prefix":"10.1016","volume":"41","author":[{"given":"Himanshu","family":"Pophale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lily","family":"Llorens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Iwanowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjeet","family":"Gutte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Chavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anasuya","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harsha","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Snehal","family":"Palwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hariharan","family":"Periasamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahesh","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balaji","family":"Veeraraghavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin","family":"Bhagwat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lansea.2025.100666_bib1","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3389\/fcimb.2016.00098","article-title":"Macrolide resistance in Streptococcus pneumoniae","volume":"6","author":"Schroeder","year":"2016","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.lansea.2025.100666_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.rechem.2022.100757","article-title":"WCK 4873 (INN: nafithromycin): structure\u2013activity relationship (SAR) identifying a novel lactone ketolide with activity against Streptococcus pneumoniae (SPN) and Streptococcus pyogenes (SPY)","volume":"5","author":"Bhavsar","year":"2023","journal-title":"Results Chem"},{"key":"10.1016\/j.lansea.2025.100666_bib3","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1007\/s00044-024-03281-5","article-title":"Nafithromycin (MIQNAF\u00ae): ultramodern lactone ketolide designed to treat community acquired bacterial pneumonia (CABP)","volume":"33","author":"Bhawsar","year":"2024","journal-title":"Med Chem Res"},{"key":"10.1016\/j.lansea.2025.100666_bib4","article-title":"Activity of novel lactone ketolide nafithromycin against multicentric invasive and non-invasive pneumococcal isolates collected in India","volume":"3","author":"Veeraraghavan","year":"2021","journal-title":"JAC Antimicrob Resist"},{"key":"10.1016\/j.lansea.2025.100666_bib5","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01230-17","article-title":"In vitro activity of the novel lactone ketolide nafithromycin (WCK 4873) against contemporary clinical bacteria from a global surveillance program","volume":"61","author":"Flamm","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.lansea.2025.100666_bib6","article-title":"In vitro activity of lactone ketolide nafithromycin (WCK 4873) against Streptococcus pneumoniae isolates enriched with macrolide-resistance phenotype collected from mainland China","volume":"4","author":"Zhou","year":"2022","journal-title":"JAC Antimicrob Resist"},{"key":"10.1016\/j.lansea.2025.100666_bib7","series-title":"In vitro activities of investigational ketolide WCK 4873 (nafithromycin) and other antimicrobial agents against human Mycoplasmas and Ureaplasmas. P-480","author":"Waites","year":"2016"},{"issue":"65","key":"10.1016\/j.lansea.2025.100666_bib8","article-title":"In vitro activity of nafithromycin (WCK 4873) against Chlamydia pneumoniae","volume":"17","author":"Kohlhoff","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.lansea.2025.100666_bib9","series-title":"In Vitro intracellular activity of A novel lactone ketolide WCK 4873 against Legionella pneumophila. Abstract 1436","author":"Dubois","year":"2016"},{"key":"10.1016\/j.lansea.2025.100666_bib10","series-title":"WCK 4873 (nafithromycin): impact of hyper ermB induction in S. Pneumoniae and S. aureus on the activity of ketolides. P-1350. Poster presented at the 27th European congress of clinical microbiology and infectious diseases (ECCMID), April 22nd - 26th","author":"Khande","year":"2017"},{"key":"10.1016\/j.lansea.2025.100666_bib11","series-title":"WCK 4873 (nafithromycin): PK\/PD analysis for H. influenzae (HI) through murine lung infection model. Abstract OS1017. Presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 22nd - 26th","author":"Satav","year":"2017"},{"key":"10.1016\/j.lansea.2025.100666_bib12","series-title":"WCK 4873 (nafithromycin): in vitro and in vivo activity of novel lactone-ketolide against clinically relevant S. Pneumoniae (SPN) resistotypes and methicillin-sensitive S. aureus (MSSA). Poster 456","author":"Satav","year":"2016"},{"key":"10.1016\/j.lansea.2025.100666_bib13","series-title":"WCK 4873 (nafithromycin): PK\/PD analysis against S. Pneumoniae (SPN) including telithromycin-non-susceptible (TEL-NS) strains through murine-lung infection model. Poster 463","author":"Takalkar","year":"2016"},{"key":"10.1016\/j.lansea.2025.100666_bib14","series-title":"WCK 4873 (nafithromycin): in vivo lung infection studies against macrolide-resistant (MR) and telithromycin-non-susceptible (TEL-NS) pneumococci. Poster 484","author":"Bhagwat","year":"2016"},{"key":"10.1016\/j.lansea.2025.100666_bib15","series-title":"Investigating the role of post-antibiotic effect (PAE) in evolving an once-daily regimen for a novel macrolide antibiotic, nafithromycin (MIQNAFTM). Poster 59. Poster presented at CIDSCON 2024, August 15-18","author":"Joshi","year":"2024"},{"key":"10.1016\/j.lansea.2025.100666_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2020.155049","article-title":"Pretreatment of nafithromycin attenuates inflammatory response in murine lipopolysaccharide induced acute lung injury","volume":"129","author":"Trivedi","year":"2020","journal-title":"Cytokine"},{"key":"10.1016\/j.lansea.2025.100666_bib17","series-title":"In vitro bactericidal activity of nafithromycin (MIQNAF) against resistant respiratory isolates of Streptococcus pneumoniae (SPN), Streptococcus pyogenes (SPY) and Staphylococcus aureus (STA). Poster 60. Poster presented at CIDSCON 2024, August 15-18","author":"Joshi","year":"2024"},{"key":"10.1016\/j.lansea.2025.100666_bib18","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01096-17","article-title":"Comparison of plasma and intrapulmonary concentrations of nafithromycin (WCK 4873) in healthy adult subjects","volume":"61","author":"Rodvold","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.lansea.2025.100666_bib19","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01253-19","article-title":"Safety, tolerability and pharmacokinetics of oral nafithromycin (WCK4873) after single or multiple doses and effects of food on single-dose bioavailability in healthy adult subjects","volume":"63","author":"Iwanowski","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.lansea.2025.100666_bib21","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/sim.4780040211","article-title":"Comparative analysis of two rates","volume":"4","author":"Miettinen","year":"1985","journal-title":"Stat Med"},{"key":"10.1016\/j.lansea.2025.100666_bib22","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1086\/526535","article-title":"The Maxwell Finland Lecture: for the duration-rational antibiotic administration in an era of antimicrobial resistance and clostridium difficile","volume":"46","author":"Rice","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.lansea.2025.100666_bib23","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1164\/rccm.201908-1581ST","article-title":"Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American thoracic society and infectious diseases society of America","volume":"200","author":"Metlay","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.lansea.2025.100666_bib24","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1001\/jamainternmed.2016.3646","article-title":"The new antibiotic Mantra-\"Shorter is better\"","volume":"176","author":"Spellberg","year":"2016","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.lansea.2025.100666_bib25","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.cmi.2022.08.024","article-title":"Short-course antibiotics for common infections: what do we know and where do we go from here?","volume":"29","author":"Lee","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.lansea.2025.100666_bib26","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1001\/jamainternmed.2016.3633","article-title":"Duration of antibiotic treatment in community-acquired pneumonia: a multicenter randomized clinical trial","volume":"176","author":"Uranga","year":"2016","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.lansea.2025.100666_bib27","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.cmi.2022.04.005","article-title":"The Shorter Is Better movement: past, present, future","volume":"29","author":"Spellberg","year":"2023","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"10.1016\/j.lansea.2025.100666_bib28","first-page":"163","article-title":"Global phase 2 study comparing efficacy and safety of oral nafithromycin (MIQNAFTM) with moxifloxacin in adult patients with community-acquired bacterial pneumonia (CABP). Abstract no. 129","volume":"2","author":"Patel","year":"2024","journal-title":"J Clin Infect Dis Society"},{"key":"10.1016\/j.lansea.2025.100666_bib29","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jgar.2021.10.021","article-title":"Pooled microbiological findings and efficacy outcomes by pathogen in adults with community-acquired bacterial pneumonia from the Lefamulin Evaluation against Pneumonia (LEAP) 1 and LEAP 2 phase 3 trials of lefamulin versus moxifloxacin","volume":"29","author":"Paukner","year":"2022","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.lansea.2025.100666_bib30","article-title":"A phase 3 study to compare delafloxacin with moxifloxacin for the treatment of adults with community-acquired bacterial pneumonia (DEFINE-CABP)","volume":"7","author":"Horcajada","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.lansea.2025.100666_bib31","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1056\/NEJMoa1800201","article-title":"Omadacycline for community-acquired bacterial pneumonia","volume":"380","author":"Stets","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lansea.2025.100666_bib32","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00151-21","article-title":"Outpatient fluoroquinolone prescription fills in the United States, 2014 to 2020: assessing the impact of food and drug administration safety warnings","volume":"65","author":"Buehrle","year":"2021","journal-title":"Antimicrob Agents Chemother"}],"container-title":["The Lancet Regional Health - Southeast Asia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772368225001374?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772368225001374?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T04:53:36Z","timestamp":1760158416000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772368225001374"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":31,"alternative-id":["S2772368225001374"],"URL":"https:\/\/doi.org\/10.1016\/j.lansea.2025.100666","relation":{},"ISSN":["2772-3682"],"issn-type":[{"value":"2772-3682","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of a 3-day once-daily regimen of oral nafithromycin in comparison to oral moxifloxacin for the treatment of community-acquired bacterial pneumonia in adults: a phase III, randomized, double-blind controlled trial","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Southeast Asia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lansea.2025.100666","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100666"}}